Search for: "PAR PHARMACEUTICALS"
Results 141 - 160
of 303
Sort by Relevance
|
Sort by Date
2 Jan 2013, 11:54 am
Par Pharmaceutical (Sept. 28, 2012). [read post]
19 Oct 2012, 6:13 pm
The majority of the assets in these 18 markets would be divested to Par Pharmaceutical, Inc. [read post]
18 Oct 2012, 1:00 am
Par Pharmaceutical Inc., the Federal Circuit upheld the district court’s determination that the patents at issue were not invalid as obvious and were infringed by the subject Abbreviated New Drug Applications (ANDAs). [read post]
13 Sep 2012, 9:59 pm
Par Pharmaceutical, Inc., thereby allowing Santarus to keep Par's generic version of Zegerid® off the market until the expiration of the Orange Book-listed patents. [read post]
11 Sep 2012, 5:30 am
Par Pharmaceutical, Inc., which dealt with whether a drug covered by an Abbreviated New Drug Application (ANDA) infringed the patents owned by that patent owner relative to the proton pump inhibitors (PPI) product omeprazole. [read post]
5 Sep 2012, 5:51 pm
Par [read post]
5 Sep 2012, 5:45 pm
California - The Federal Circuit on Tuesday gave Santarus Inc. another chance to prove that its patents for the heartburn drug Zegerid are valid and that Par Pharmaceuticals Inc.'s proposed generic version would infringe those patents. [read post]
19 Jul 2012, 8:07 am
As matters stand right now, this is clearly not the case when it comes to patent protection for pharmaceutical inventions. [read post]
18 Jul 2012, 12:53 pm
Before reaching an agreement to sell to TPG, Par Pharmaceutical melded the two conventional approaches in negotiating its sale. [read post]
18 Jul 2012, 12:53 pm
Before reaching an agreement to sell to TPG, Par Pharmaceutical melded the two conventional approaches in negotiating its sale. [read post]
16 Jul 2012, 1:24 pm
Some analysts believe that the TPG agreement undervalues Par Pharmaceutical, indicating that other suitors could surface. [read post]
16 Jul 2012, 7:56 am
TPG Capital has agreed to buy the generic drug maker Par Pharmaceutical in a $1.9 billion leveraged buyout, as merger activity in the health care industry continues to heat up. [read post]
16 Jul 2012, 7:56 am
TPG agreed on Monday to buy Par Pharmaceutical, a maker of generic drugs, in a $1.9 billion leveraged buyout, as merger activity in the health care industry continues to heat up. [read post]
16 Jul 2012, 7:56 am
TPG agreed on Monday to buy Par Pharmaceutical, a maker of generic drugs, in a $1.9 billion leveraged buyout, as merger activity in the health care industry continues to heat up. [read post]
5 Jul 2012, 1:04 am
” (par. 35). [read post]
7 May 2012, 5:51 am
In order to provide article 5 par. 3 with real effectiveness, the Court conducts a systematic and coherent interpretation of articles 5 par.3, 5 par. 1, 6 par. 1, 9 par. 1 and of the recitals 17 and 18 of the Directive. [read post]
25 Apr 2012, 1:56 pm
The FTC brought the case in 2009 against Solvay Pharmaceuticals and generic manufacturers Watson Pharmaceuticals, Par Pharmaceutical, and Paddock Laboratories over a “pay for delay” or “reverse payment” patent infringement settlement agreement related to patents for AndroGel—a testosterone replacement drug often used by men whose bodies do not produce normal levels of testosterone. [read post]
19 Apr 2012, 8:17 pm
Par Pharmaceutical Inc. 1:12-cv-00419; filed April 4, 2012 in the District Court of Delaware Infringement of U.S Patent Nos. 7,619,004 ("Methods for Concomitant Administration of Colchicine and Macrolide Antibiotics," issued November 17, 2009), 7,601,758 ("Methods for Concomitant Administration of Colchicine and Macrolide Antibiotics in the Treatment of Gout Flares," issued October 13, 2009), 7,820,681 ("Methods for Concomitant Administration of Colchicine… [read post]
15 Apr 2012, 8:47 pm
• Defendants: Par Pharmaceutical Companies Inc.; Par Pharmaceutical Inc. [read post]
1 Apr 2012, 8:58 am
H.R. 4332 would take OGD out of OPS and make it an office on par with the Office of New Drugs. [read post]
